At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,041 enrolled
Drug / intervention
liraglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.
In Brief
A Phase 3 clinical trial evaluating liraglutide, rosiglitazone, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 1,041 participants across 127 sites in 23 countries.
Detailed Summary
This trial is conducted globally (the United States of America excepted). This trial is designed to show the effect of treatment with liraglutide when added to existing glimepiride therapy and to compare this to both glimepiride monotherapy and to rosiglitazone as add-on therapy to glimepiride.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesArgentina, Australia, Brazil, Bulgaria, Croatia, Czechia, Finland, France, Greece, India, Israel, Italy, Malaysia, Philippines, Poland, Romania, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey (Türkiye)
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2006
Enrollment StartMay 2006
Primary CompletionMay 2007
TodayJul 2026
First PostedApr 26, 2006
Enrollment StartMay 1, 2006
Primary CompletionMay 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 20.2 years ago
Interventions
liraglutidedrug
rosiglitazonedrug
glimepiridedrug